CX Institutional Buys Shares of 513 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CX Institutional acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 513 shares of the company's stock, valued at approximately $215,000.

A number of other hedge funds have also recently made changes to their positions in IDXX. Hurley Capital LLC purchased a new stake in IDEXX Laboratories in the fourth quarter valued at about $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter worth approximately $30,000. Colonial Trust Co SC boosted its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares during the last quarter. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. grew its holdings in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the company's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director now owns 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Trading Down 0.8%

IDXX stock traded down $4.22 during trading on Friday, reaching $522.70. 411,464 shares of the stock traded hands, compared to its average volume of 650,612. The business's 50 day moving average price is $473.11 and its 200-day moving average price is $444.45. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $530.73. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market capitalization of $42.04 billion, a PE ratio of 48.99, a P/E/G ratio of 3.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the prior year, the business earned $2.71 earnings per share. The company's revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent analyst reports. Stifel Nicolaus upped their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Morgan Stanley upped their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Leerink Partners increased their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research note on Wednesday. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average price target of $546.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.